AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04996771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Etoposide,Cisplatin,Toripalimab
Description: In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed.
Study NCT04996771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Etoposide,Cisplatin
Description: In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed.
Study NCT06630572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Patients randomized to receive Rifaximin for 14 days
Study NCT06004180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996
Description: Hard capsule, orally, per schedule specified in the arm description.
Study NCT04482712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
Study NCT04482712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of investigational drug placebo for up to 4 weeks while hospitalized
Study NCT04962048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse-synchronized negative pressure (PSNP) device
Description: The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
Study NCT04962048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control - no intervention
Description: The other leg serves as non-treated control
Study NCT04786392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein supplement
Description: 5 mg lutein supplement.
Study NCT04786392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food, blended
Description: 5 mg lutein from baby spinach, blended.
Study NCT04786392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food, unprocessed
Description: 5 mg lutein from baby spinach, in whole food form.
Study NCT06630572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to receive Placebo for 14 days
Study NCT06705530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hem101
Description: CAR-T lymphocytes specific to CD19 B-cell antigen
Study NCT06705023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)
Description: Intracardial venous injection of fresh, uncultured, autologous, adipose-derived regenerative cells isolated from lipoaspirate at the point of care.
Study NCT06705023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of patient's best guideline based medical treatment
Description: Patients will receive continuation of their best guideline based medical treatment.
Study NCT06712212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernias repair: Desarda
Description: A splitting incision is made in this sutured medial leaf, partially separating a strip 1.5-2 cm wide. This splitting incision is extended medially up to the pubic symphysis and 1-2 cm beyond the abdominal ring laterally. The medial insertion and lateral continuation of this strip is kept intact. The upper free border of the strip is now sutured to the internal oblique with number 1 Monofilament Polydioxanone Violet continuous sutures all along its length. This will result in the strip of the EOA being placed behind the cord to form a new posterior wall of the inguinal canal. The spermatic cord is placed in the inguinal canal and the lateral leaf of the EOA is sutured to the newly formed medial leaf of the EOA in front of the cord. As before, number 1 Monofilament Polydioxanone Violet continuous sutures were used. Undermining of the newly formed medial leaf on both its surfaces and excision of the bulky cremasteric muscle facilitate its approximation to the lateral leaf
Study NCT06712212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair: Darn
Description: Skin and fascia are incised using a regular, oblique inguinal incision to expose the external oblique aponeurosis (EOA) the inguinal canal is opened into by dividing the external oblique aponeurosis through the external ring. After dealing with the hernia sac, a 0-size monofilament suture was used to reconstruct the inguinal bed with a tension-free darn starting with a good strong bite of the tough tendinous structures near the pubic tubercle and emerging out through the lateral edge of the internal oblique/rectus sheath from one side and through the inguinal ligament on the other side. The loosely interwoven bites continued laterally and the back-forming two rows of continuous stitches were placed in a staggered manner to spread the tension between the fibres of the inguinal ligament. Afterwards, the external oblique and other superficial layers with the skin are classically closed
Study NCT06712225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anomia therapy: semantic feature analysis and phonological components analysis;
Description: After the initial assessment + functional Magnetic Resonance Imaging (fMRI), participants will first receive their usual speech therapy rehabilitation for 10 to 15 sessions (baseline phase), and then enter the experimental phase: 18 sessions (3 per week) of either anomia therapy alone or anomia therapy + executive function training, according to the arm they were assigned to. All sessions will last 45 minutes. Naming skills will be repeatedly measured during both phases. A second assessment of language + fMRI will then be conducted and participants will return to their usual rehabilitation. Four weeks later, a final assessment of naming and discourse will be conducted.
Study NCT06074497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KGX101 and Envafolimab
Description: Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
Study NCT06712225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anomia therapy: semantic feature analysis and phonological components analysis;
Description: After the initial assessment + functional Magnetic Resonance Imaging (fMRI), participants will first receive their usual speech therapy rehabilitation for 10 to 15 sessions (baseline phase), and then enter the experimental phase: 18 sessions (3 per week) of either anomia therapy alone or anomia therapy + executive function training, according to the arm they were assigned to. All sessions will last 45 minutes. Naming skills will be repeatedly measured during both phases. A second assessment of language + fMRI will then be conducted and participants will return to their usual rehabilitation. Four weeks later, a final assessment of naming and discourse will be conducted.
Study NCT06712225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive function training: computerized equipment
Description: Executive function training will be conducted by means of a computerized material specifically designed for the study, consisting of verbal and nonverbal exercises targeting, always in the same order, inhibition, shifting, working memory and planning functions, with a gradient of difficulty. Training will always be done at the beginning of the session, during 20 minutes, before anomia therapy.
Study NCT06711419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: f caudal neuroplasty using epidural catheter combined with Pulsed Radiofrequency (PRF) versus Pulsed Radiofrequency (PRF) alone
Description: Fluoroscopic guidance was used in all cases with a C-arm system. The patient was prone with a pillow under the lower abdomen. Anteroposterior (AP) images were taken to identify the target level. The C-arm was angled 15-30° to project the spinous process over the contralateral facet (scotty dog view). Skin was infiltrated with lidocaine, and a 22-gauge RF cannula was advanced under fluoroscopy. The tip was positioned in the dorsal-cranial quadrant of the intervertebral foramen on lateral images. PRF was applied with 4 cycles at 42°C for 8 minutes after sensory/motor testing. Injections of lidocaine and triamcinolone followed. In caudal neuroplasty, an epidural catheter was placed using the sacral hiatus as a guide. Fluoroscopy confirmed catheter position. Contrast was injected to confirm spread, and hyaluronidase and lidocaine were administered. Afterward, the catheter was removed.
Study NCT06712056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: study of focusing attention
Study NCT06711185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Patients in this group will receive 1 tablet of 10mg dapagliflozin daily for 9 months, starting 7-10 days before chemotherapy treatment.
Study NCT05688007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: parathyroid hormone level
Description: Serum level of parathyroid hormone
Study NCT05688007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum electrolytes
Description: Serum levels of: magnesium, phosphorus, calcium, and albumin
Study NCT05016219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circadian-Effective Light
Description: Narrowband blue light
Study NCT05016219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Light
Description: 40 hertz (Hz) flicker
Study NCT05016219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Light
Description: Narrowband red light
Study NCT05016219 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Light
Description: Narrowband red light
Study NCT05016219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Rhythmic Light
Description: Random flicker for placebo rhythmic effect
Study NCT05016219 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Rhythmic Light
Description: Random flicker for placebo rhythmic effect
Study NCT05226598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
Study NCT06711185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive 1 placebo tablet per day, with identical characteristics to the group receiving dapagliflozin, for 9 months, starting 7-10 days before the start of chemotherapy treatment
Study NCT06714539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Specific Virtual Reality Stimulation
Description: A novel virtual reality (VR) simulator for spine procedures that will take patient specific medical imaging (3D scans) and create a virtual patient that surgical procedures can be performed on.
Study NCT06712043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised Exercise
Description: An individualized exercise program consisting of aerobic exercises, strength exercises and balance exercises. The exercises will be prescribed via the Physitrack app.
Study NCT05144841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2140 (zilovertamab vedotin)
Description: IV infusion of 2.5 mg/kg
Study NCT05144841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2140 (zilovertamab vedotin)
Description: IV infusion of 2.25 mg/kg
Study NCT05034432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-Op Prophylactic VT ablation
Description: For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping
Study NCT05034432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Management
Description: To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
Study NCT05768802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoelectric Implantable Recording Array (MIRA)
Description: The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.
Study NCT06376734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
Study NCT06228248 — intervention group
Intervention type: OTHER
Intervention: metagenomics
Description: Feces used for metagenomic testing
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
Study NCT04832152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OT4ASD
Description: Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
Study NCT05888233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
Study NCT04564014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISSS
Description: The ISSS aims to help participants acquire problem-solving (e.g., interpersonal problems) and time management based on the treatment manual of the therapy. Video introductions for each session and example teacher characters who depict the targeted problems and demonstrate implementation of coping/management techniques in a variety of situations. ISSS will use metaphors, daily examples, and lively narrative stories to enhance motivation for participation and understanding of the intervention contents. Session 2-5 will assign exercise and homework. Within 48 hours, participants will receive personalized written feedback (e.g., suggestions) from an e-Coach on the exercises they have completed. Participants can contact e-Coaches via the online system if they have any questions regarding the contents. Questions that beyond the contents will be referred to the health psychologist (PI) by e-Coaches.
Study NCT04564014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ISSS
Description: The ISSS aims to help participants acquire problem-solving (e.g., interpersonal problems) and time management based on the treatment manual of the therapy. Video introductions for each session and example teacher characters who depict the targeted problems and demonstrate implementation of coping/management techniques in a variety of situations. ISSS will use metaphors, daily examples, and lively narrative stories to enhance motivation for participation and understanding of the intervention contents. Session 2-5 will assign exercise and homework. Within 48 hours, participants will receive personalized written feedback (e.g., suggestions) from an e-Coach on the exercises they have completed. Participants can contact e-Coaches via the online system if they have any questions regarding the contents. Questions that beyond the contents will be referred to the health psychologist (PI) by e-Coaches.
Study NCT04564014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials
Description: Participants will recieve education materials addressing the following issues: (1) introduction to mental health and mental illness; (2) signs and symptoms of depression; (3) treatment of depression and available community resources; (4) signs and symptoms of anxiety; (3) treatment of anxiety and available community resources. The education materials will be carefully developed by the health psychologists and clinical psychologist of the research team who are very experienced in education intervention for mental and emotional health.
Study NCT04564014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Materials
Description: Participants will recieve education materials addressing the following issues: (1) introduction to mental health and mental illness; (2) signs and symptoms of depression; (3) treatment of depression and available community resources; (4) signs and symptoms of anxiety; (3) treatment of anxiety and available community resources. The education materials will be carefully developed by the health psychologists and clinical psychologist of the research team who are very experienced in education intervention for mental and emotional health.
Study NCT05626335 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoral scan
Description: On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0), using 3Shape Trios 4 (3Shape, Copenhagen, Denmark). The scans were repeated after a month. The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3).
Study NCT05531942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Diterpene Lactone Meglumine Injection
Description: The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
Study NCT05531942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
Study NCT05531942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
Study NCT05143411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRE-test
Description: we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
Study NCT05226195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile Kinesio Taping
Description: The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
Study NCT05061836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer acetate
Description: Patient will receive Acetate Ringer's solution (Acetar) infused at maintenance rate
Study NCT05061836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25%Dextrose equivalence
Description: 5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
Study NCT05061836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5%Dextrose equivalence
Description: 5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
Study NCT05061836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5
Description: 5%dextrose in normal saline (5%DNSS) infused with maintenance rate
Study NCT05199844 — intervention group
Intervention type: DEVICE
Intervention: Apple Watch
Description: Apple Watch device measures heart rate and oxygen saturation
Study NCT06466642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©
Description: The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.